Novo Nordisk’s weight-loss pill boom faces price war test – Image for illustrative purposes only (Image credits: Unsplash)
Novo Nordisk achieved a strong launch for its oral Wegovy weight-loss pill in the United States this year. Data from IQVIA showed roughly 721,000 prescriptions filled in the first quarter of 2026, outpacing initial projections.[1][2] The momentum highlights the appeal of pill-based GLP-1 treatments amid patient preferences for needle-free options. Investors now scrutinize whether this volume can counterbalance escalating price competition as the company prepares to report first-quarter earnings.[3]
Prescriptions Exceed Forecasts in Early Going
The oral Wegovy, which shares the active ingredient semaglutide with its injectable counterpart, debuted in January 2026. Telehealth providers reported a doubling in new patient sign-ups shortly after availability, with platforms like LifeMD handling 600 to 1,000 daily starts.[3] BMO Capital Markets analyst Evan Seigerman noted the figures topped expectations, though IQVIA’s tally omitted some telehealth channels, implying even higher real-world uptake.
Patients gravitated toward the lowest 1.5 mg starter dose, accounting for about 450,000 of the total prescriptions. Priced at $149 per month, this entry-level option drew cash-paying customers wary of injection costs. Higher-dose scripts increased more gradually, reflecting typical treatment ramps that span months.
Revenue Realities Temper the Volume Story
Strong prescription counts did not guarantee robust sales. Analysts estimated first-quarter pill revenue near $1 billion, roughly 12% short of consensus forecasts, largely due to heavy reliance on the budget starter dose.[1] Barclays analyst James Gordon pointed out potential patient behaviors, such as lingering on low doses for cost reasons or discontinuing therapy early.
Novo Nordisk invested heavily in production capacity, including a $500 million facility in Ireland, to meet anticipated demand. The company entered a quiet period ahead of its May 6 earnings disclosure, where initial pill sales data will draw intense focus. Early signs suggested the product expanded the GLP-1 market by attracting injection-hesitant users, including more men.
Eli Lilly’s Foundayo Enters the Arena
Competition sharpened in April when Eli Lilly secured approval for Foundayo, its own oral obesity pill. Lilly reported solid first-quarter growth for Zepbound and Mounjaro, bolstering shares for both firms.[1] Foundayo notched over 20,000 starters in its first weeks, with 1,000 daily additions – 80% new to GLP-1s – though Novo maintained a three-month lead.
Lilly emphasized manufacturing advantages to avoid shortages, while Novo leaned on brand familiarity and marketing pushes like Super Bowl spots. Analysts viewed the pill race as fluid, with Lilly’s broader pipeline giving it an edge in investor eyes. Novo faced additional headwinds from generic semaglutide in markets like India and China.
What Matters Now
Market Value Reflects Heightened Uncertainty
Novo Nordisk’s valuation soared to $650 billion in mid-2024 before retreating to 2021 levels, shedding over $400 billion. Shareholder Lukas Leu acknowledged the solid launch but questioned its ability to offset accelerating price drops. “The launch is definitely strong,” Leu said. “What we don’t know yet is whether it will compensate Novo for the price decline, which is faster.”[1]
Mikael Bak, head of the Danish Shareholders’ Association, likened the period to an exam. “We are in the middle of the exam period,” Bak stated. “What I will be looking for is whether they are increasingly able to go from being rather defensive to being more offensive.”[1] Global obesity drug sales projections, once pegged at $150 billion annually next decade, now appear shaky.
The Wegovy pill offers Novo a chance to reclaim momentum in a market transformed by GLP-1 therapies. Earnings results will clarify if volume gains can sustain profitability amid rivalry and cost squeezes. For now, the boom underscores the category’s potential while testing the Danish drugmaker’s adaptability.
